QS Investors’s Ultragenyx Pharmaceutical RARE Stock Holding History

QS Investors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$371K	Hold	3,884	–	–	﹤0.01%	856
2021 Q1	$443K	Buy	3,884 +50	+1%	+$6.81K	0.01%	841
2020 Q4	$531K	Sell	3,834 -66	-2%	-$7.83K	0.01%	760
2020 Q3	$321K	Sell	3,900 -12,200	-76%	-$1.01M	﹤0.01%	895
2020 Q2	$1.26M	Hold	16,100	–	–	0.02%	655
2020 Q1	$716K	Hold	16,100	–	–	0.01%	754
2019 Q4	$695K	Hold	16,100	–	–	0.01%	848
2019 Q3	$689K	Hold	16,100	–	–	0.01%	867
2019 Q2	$1.02M	Buy	16,100 +15,200	+1,689%	+$967K	0.01%	788
2019 Q1	$63K	Sell	900 -7	-0.8%	-$400	﹤0.01%	1477
2018 Q4	$40K	Hold	907	–	–	﹤0.01%	1469
2018 Q3	$69K	Hold	907	–	–	﹤0.01%	1456
2018 Q2	$70K	Hold	907	–	–	﹤0.01%	1474
2018 Q1	$46K	Hold	907	–	–	﹤0.01%	1487
2017 Q4	$42K	Hold	907	–	–	﹤0.01%	1506
2017 Q3	$48K	Hold	907	–	–	﹤0.01%	1532
2017 Q2	$56K	Hold	907	–	–	﹤0.01%	1486
2017 Q1	$61K	Buy	907 +900	+12,857%	+$68.6K	﹤0.01%	1464
2016 Q4	$1K	Hold	7	–	–	﹤0.01%	1709
2016 Q3	$1K	Buy	7 +2	+40%	+$128	﹤0.01%	1698
2016 Q2	$1K	Buy	+5	New	+$323	﹤0.01%	1745
2016 Q1	–	Sell	-3	Closed	-$1K	–	2047
2015 Q4	$1K	Buy	+3	New	+$300	﹤0.01%	1769

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

QS Investors's RARE Position: Q2 2021 in Review

QS Investors held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2021 at 3,884 shares worth $371K. The position accounts for ﹤0.01% of the portfolio, ranked #856.

QS Investors first reported a position in RARE in Q4 2015 and has held it in 22 quarters since. The position peaked at $1.26M in Q2 2020. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

QS Investors held 3,884 shares of Ultragenyx Pharmaceutical worth $371K as of Q2 2021.
QS Investors left its Ultragenyx Pharmaceutical share count unchanged in Q2 2021.
Ultragenyx Pharmaceutical made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #856 holding.
QS Investors first reported a position in Ultragenyx Pharmaceutical in Q4 2015 and has held it in 22 quarters since.
QS Investors's Ultragenyx Pharmaceutical position peaked at $1.26M in Q2 2020.
241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.